Godfrey Capital
VC Fund
Godfrey Capital is a VC fund focused on Biotechnology and FinTech. An investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Godfrey Capital invests in
Stages Godfrey Capital invests in
Countries Godfrey Capital invests in
Investment Focus
Industry
- Biotechnology 3 (38%)
- FinTech 1 (13%)
- Medical 1 (13%)
- Database 1 (13%)
- Software 1 (13%)
Stage
- Seed 2 (25%)
- Series B 2 (25%)
- Series A 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Peregrine Technologies
|
Peregrine creates technology to help public safety agencies make data-driven decisions, power the operations, and maintain strong community relationships. Its software fuses disconnected data across secure networks and empowers public safety leaders with new ways to search, analyze, and collaborate. The company delivers industry-leading privacy andsecurity controls to help government institutions unlock complex data workflows, enable new types of public-private partnerships, and build trust with the communities they serve. | $250M / Series D / Jun 22, 2026 | |
Junevity
|
Junevity focuses on reversing diseases of aging through novel transcription factor medicines. The company leverages six years of breakthrough research from UCSF to develop next-generation approaches to rejuvenation. By targeting transcription factors, Junevity aims to provide innovative treatments that can potentially rewind the biological clockand improve healthspan. | $10M / Seed / Dec 03, 2025 | |
Synthetic Design Lab
|
The Synthetic Design Lab platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs. | $20M / Seed / Apr 23, 2025 | |
|
Peregrine Technologies
|
Peregrine creates technology to help public safety agencies make data-driven decisions, power the operations, and maintain strong community relationships. Its software fuses disconnected data across secure networks and empowers public safety leaders with new ways to search, analyze, and collaborate. The company delivers industry-leading privacy andsecurity controls to help government institutions unlock complex data workflows, enable new types of public-private partnerships, and build trust with the communities they serve. | $190M / Series C / Mar 04, 2025 | |
|
Junevity
|
Junevity focuses on reversing diseases of aging through novel transcription factor medicines. The company leverages six years of breakthrough research from UCSF to develop next-generation approaches to rejuvenation. By targeting transcription factors, Junevity aims to provide innovative treatments that can potentially rewind the biological clockand improve healthspan. | $10M / Seed / Feb 13, 2025 | |
|
Peregrine Technologies
|
Peregrine creates technology to help public safety agencies make data-driven decisions, power the operations, and maintain strong community relationships. Its software fuses disconnected data across secure networks and empowers public safety leaders with new ways to search, analyze, and collaborate. The company delivers industry-leading privacy andsecurity controls to help government institutions unlock complex data workflows, enable new types of public-private partnerships, and build trust with the communities they serve. | $30M / Series B / May 01, 2024 | |
Vontive
|
A first-of-its-kind embedded mortgage platform, Vontive creates an entirely new and digital way to finance investment properties. Our no-code, white-label solution empowers any business serving real estate investors to launch its own investment-property mortgage business in 1-2 weeks. Vontive creates a new revenue stream for these retail brands,integrates financial institutions through a debt marketplace, and opens the market for new investors to participate in real estate. Our company was founded by Freddie Mac and Palantir alumni who have nearly four decades of experience in the mortgage and financial services industry. | $25M / Series B / Apr 07, 2022 | |
Azitra
|
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $14M / Series A / Oct 15, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Godfrey Capital invest in?
Godfrey Capital invests primarily in Biotechnology, FinTech and Medical startups, most often at Seed and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Godfrey Capital last invest?
The most recent investment recorded for Godfrey Capital closed in Jun 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
